Zenith Nano™ Peptides
Zenith Nano™ Peptides are injectable and nasal spray peptide products.
| Product | Format | Per Bottle | Per Spray | Sprays | Details |
|---|---|---|---|---|---|
| PT-141 / Oxytocin | Nasal Spray | 5 mg / 10 mg | 31 mcg / 62 mcg per spray | 160 | View Details |
| GHK-Cu | Nasal Spray | 50 mg | 312 mcg per spray | 160 | View Details |
| MOTS-C | Nasal Spray | 20 mg | 125 mcg per spray | 160 | View Details |
| NAD+ (Injectable) | Injectable | 500 mg | — | — | View Details |
| NAD+ | Nasal Spray | 500 mg | 3.12 mg per spray | 160 | View Details |
| BPC-157 (10 mg) / TB-500 | Nasal Spray | 10 mg / 10 mg | 62 mcg / 62 mcg per spray | 160 | View Details |
| DSIP | Nasal Spray | 8 mg | 50 mcg per spray | 160 | View Details |
| Selank | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| Semax | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| CJC-1295 / Ipamorelin | Nasal Spray | 10 mg / 10 mg | 62 mcg / 62 mcg per spray | 160 | View Details |
| Tesamorelin | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| GLP-1 Analog | Nasal Spray | 20 mg | 125 mcg per spray | 160 | View Details |
| Dual Agonist GLP-1 + GIP | Nasal Spray | 20 mg / 40 mg | 125 mcg / 250 mcg per spray | 160 | View Details |
| Triple Agonist GLP-1/GIP/Glucagon | Nasal Spray | 20 mg / 40 mg | 125 mcg / 250 mcg per spray | 160 | View Details |
| Triple Agonist / GLP-1 | Nasal Spray | 25 mg / 40 mg | 156 mcg / 250 mcg per spray | 160 | View Details |
| Oxytocin | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| PT-141 | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| PT-141 / Oxytocin / Tesamorelin | Nasal Spray | 10 mg / 3 mg / 10 mg | 62 mcg / 31 mcg / 62 mcg per spray | 160 | View Details |
| Epitalon | Nasal Spray | 100 mg | 625 mcg per spray | 160 | View Details |
| GHK-Cu / KPV | Nasal Spray | 50 mg / 10 mg | 312 mcg / 62 mcg per spray | 160 | View Details |
| SS-31 | Nasal Spray | 25 mg | 156 mcg per spray | 160 | View Details |
| BPC-157 | Nasal Spray | 30 mg | 187 mcg per spray | 160 | View Details |
| TB-500 | Nasal Spray | 30 mg | 187 mcg per spray | 160 | View Details |
| KPV | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| Thymosin Alpha-1 | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
| Thymosin Alpha-1 / KPV | Nasal Spray | 10 mg / 10 mg | 62 mcg / 62 mcg per spray | 160 | View Details |
| Selank / Semax | Nasal Spray | 15 mg / 15 mg | 94 mcg / 94 mcg per spray | 160 | View Details |
| CJC-1295 | Nasal Spray | 10 mg | 62 mcg per spray | 160 | View Details |
PROPRIETARY DELIVERY TECHNOLOGY
Zenith Nano™ Spray System
Nasal delivery is facilitated with the Zenith Nano™ Spray System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.
Lipid disruption & cation exchange
Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.
Dual-polarity solubilization
Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.
Keratin modulation & partitioning
Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).
Superior loading vs. lipid carriers
Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Zenith Nano™ Spray System reaches therapeutically relevant layers.
>57× vs. saline · <10 nm (DLS)
>57× barrier penetration vs. saline in an ex vivo epithelial model (Zenith Nano™ third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.
Safety, stability & distribution
ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.